ClinicalTrials.gg
CompletedNCT00594464NEUPOSUpdated Oct 2, 2014Results posted

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

A Phase 4 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed at 12 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
41st of 42
14 · median 123
Started
2007
with 5 others
Phase 4
8 of 44
none open now
Registered
14th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 41st largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 8 in phase 4, and was the 14th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

Evaluation of efficacy and safety on the use of rotigotine in patients suffering from Parkinson's Disease during and after surgery requiring general anaesthesia.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • NEUPRO®
  • Parkinson's Disease (PD)
  • perioperative use
  • anaesthesia,
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has idiopathic Parkinson's disease (early- or advanced-stage), as defined by the cardinal sign bradykinesia, plus the presence of at least one of the following: resting tremor, rigidity, or postural instability and is without any other known or suspected cause of Parkinsonism.
  • Subject is scheduled for an operation requiring general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Subject has previously been treated with rotigotine.
  • Subject has a history of significant skin to adhesives or other transdermals or recent unresolved contact dermatitis or has a known allergy or hypersensitivity to rotigotine or to other components of the patch.
  • Subject is scheduled for a surgical procedure (surgery per protocol(SPP)) that requires magnetic resonance imaging or cardioversion.
  • Subject has a high probability to require extended postoperative ventilation (> 24 hours).
  • Subject has any medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    1

    Rotigotine

    Drug: Rotigotine

Interventions

  • 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch; Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h; One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery.

06

What researchers measure

Primary outcomes

  1. Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist.

    Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Patient did not show unexpected symptoms Item 2: Handling was simple Item 3: Handling wasn't time-consuming Item 4: Patch is a considerable option

    Time frame: After subject wakes up from general anesthesia

  2. Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Neurologist.

    Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Switch to patch was easily feasible Item 2: Re-switch was easily feasible Item 3: Patient did not show unexpected symptoms Item 4: Patch is a feasible option

    Time frame: 2 weeks after surgery

  3. Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Patient.

    Questionnaire including 3 items Range of sum score: 3 to 18 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Therapy with patch was easily feasible Item 2: Symptoms of Parkinson's Disease were well controlled Item 3: I felt safe with the Parkinson patch

    Time frame: 2 weeks after surgery

Secondary outcomes

  1. Plasma Concentration of Rotigotine After Use.

    Time frame: 24 hours

07

Results

Posted Jul 3, 2009

Participant flow

Participant flow — Overall Study
MilestoneRotigotine
Started14
Completed11
Not completed3
Withdrew: Withdrawal by subject1
Withdrew: Delay in operation2

Outcome measures

PrimaryEfficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist.

Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Patient did not show unexpected symptoms Item 2: Handling was simple Item 3: Handling wasn't time-consuming Item 4: Patch is a considerable option

Time frame:
After subject wakes up from general anesthesia
Reported as:
Mean · Score on scale
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist.
Score on scaleRotigotine
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist.5.0 ± 1.8
SecondaryPlasma Concentration of Rotigotine After Use.
Time frame:
24 hours
Reported as:
Mean · ng/ml
Plasma Concentration of Rotigotine After Use.
ng/mlRotigotine 2 mg/24hRotigotine 6mg/24hRotigotine 8 mg/24hRotigotine 12 mg/24hRotigotine 14 mg/24hRotigotine 16 mg/24h
Plasma Concentration of Rotigotine After Use.0.1640 ± 00.2480 ± 00.7570 ± 0.15690.8405 ± 0.33020.8689 ± 01.6958 ± 2.1951
PrimaryEfficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Neurologist.

Questionnaire including 4 items Range of sum score: 4 to 24 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Switch to patch was easily feasible Item 2: Re-switch was easily feasible Item 3: Patient did not show unexpected symptoms Item 4: Patch is a feasible option

Time frame:
2 weeks after surgery
Reported as:
Mean · Score on scale
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Neurologist.
Score on scaleRotigotine
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Neurologist.5.2 ± 2.2
PrimaryEfficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Patient.

Questionnaire including 3 items Range of sum score: 3 to 18 Range of item scores: 1 (I agree completely) to 6 (I don't agree at all) Item 1: Therapy with patch was easily feasible Item 2: Symptoms of Parkinson's Disease were well controlled Item 3: I felt safe with the Parkinson patch

Time frame:
2 weeks after surgery
Reported as:
Mean · Score on scale
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Patient.
Score on scaleRotigotine
Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Patient.3.9 ± 1.4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—4/14 (28.6%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventRotigotine
Ventricular asystoleCardiac disorders1/14
Joint dislocationInjury, poisoning and procedural complications1/14
Post procedural haematomaInjury, poisoning and procedural complications1/14
HallucinationPsychiatric disorders1/14
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRotigotine
Procedural painInjury, poisoning and procedural complications5/14
ConstipationGastrointestinal disorders3/14
NauseaGastrointestinal disorders3/14
Urinary tract infectionInfections and infestations3/14
Iron deficiencyMetabolism and nutrition disorders2/14
Sleep disorderPsychiatric disorders2/14
PruritusSkin and subcutaneous tissue disorders2/14
AnaemiaBlood and lymphatic system disorders1/14
Ear PainEar and labyrinth disorders1/14
DiarrhoeaGastrointestinal disorders1/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years2
>=65 years12
Age, Continuous
Age, Continuous(years)Rotigotine
Mean68.7 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female7
Male7
Region of Enrollment
Region of Enrollment(participants)Rotigotine
Germany14
08

Study locations

12 sites
  • Augsburg, Germany
  • Bochum, Germany
  • Bonn, Germany
  • Bremerhaven, Germany
  • Dortmund, Germany
  • Dresden, Germany
  • Hanau, Germany
  • Ingolstadt, Germany
  • Kiel, Germany
  • Schwerin, Germany
  • Stralsund, Germany
  • Ulm, Germany
09

References and documents

Publications

  • Wullner U, Kassubek J, Odin P, Schwarz M, Naumann M, Hack HJ, Boroojerdi B, Reichmann H; NEUPOS Study Group. Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm (Vienna). 2010 Jul;117(7):855-9. doi: 10.1007/s00702-010-0425-4. Epub 2010 Jun 10. PubMed 20535621 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Jan 15, 2008
Start
Sep 2007
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jul 3, 2009
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00594464
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 15, 2008
Start date
Sep 2007
Primary completion
May 2008
Completion
May 2008
Results posted
Jul 3, 2009
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion